We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.ContinueLearn More X
During next edition of Vitafoods Europe – the tradeshow taking place from 15 to 17 May 2018 in Palexpo (Geneva) – Gnosis will exclusively disclose the latest clinical results obtained from the new human clinical trial on Mythocondro®, that will be shortly published in an important scientific journal.
Gnosis will dedicate a special corner of its booth #I40 to Mythocondro®, the only vegetarian Non-Animal Chondroitin Sulfate, and will welcome customers and partners to reveal the news provided by the human study, and how these can give an input to the marketing of new finished products containing Chondroitin Sulfate.
We will show:
1. Bioavailability and pharmacokinetic profile of Mythocondro® in comparison to animal Chondroitin Sulfate (CS) in human volunteers. In particular, two distinctive characteristics of Mythocondro® – the sulfation at position 6 of the disaccharide chain (ΔDi6S) and the charge density – have been evaluated, in order to recognize if they may influence the CS ability to interact with various extracellular molecules, allowing to exert more pronounced chondroprotective effects than a CS of extractive origin.
2. Efficacy and safety of Mythocondro® supplementation in humans, to assess the effects of a low-dose of Non-Animal CS Mytochondro® in treating subjects with moderate knee osteoarthritis.
Mythocondro® has already been extensively studied and characterised through a wide range of preclinical and clinical trials, which were included in two different studies already published in the last few years (Bauerova et al. 2014; Miraglia et al. 2016).